In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

President Prabowo Subianto highlighted Indonesia's economic growth of 5.12 percent as one of the highest in the G20 and ASEAN ...

President Prabowo Subianto instructed Health Minister Budi Gunadi Sadikin to increase the number of dentists at public health ...

The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...

The rejection occurred amid broader turmoil at the FDA, which has been experiencing leadership changes, staff upheaval, and internal dysfunction. These organizational issues reportedly factored into ...

GoTo had a connection to the procurement process and mechanisms for Google Cloud at Kemendikbudristek during that time.

"These players believe the people must remain impoverished. They suck Indonesia's wealth like it's blood," Prabowo said.

Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...